세계의 줄기세포 은행 시장 : 장래 예측 - 원료 유형별, 은행 유형별, 서비스 유형별, 이용 상황별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Stem Cell Banking Market is accounted for $11.2 billion in 2025 and is expected to reach $22.2 billion by 2032 growing at a CAGR of 10.2% during the forecast period. Stem cell banking is the process of collecting, processing, and preserving stem cells for potential future medical use. These cells, typically derived from sources such as umbilical cord blood, bone marrow, or adipose tissue, have the unique ability to develop into various cell types and regenerate damaged tissues. The preserved stem cells can be used in regenerative medicine, transplantation, and the treatment of various diseases like leukemia, lymphoma, and immune disorders. Stored in cryogenic conditions, stem cell banking provides a valuable biological resource for individuals and families, ensuring access to personalized therapies and advanced medical treatments in the future.

According to the International Society for Stem Cell Research (ISSCR), the number of ongoing clinical trials using stem cells surpassed 7,000 globally, reflecting the rapid development of regenerative therapies and the increasing demand for quality-assured stem cell storage.

Market Dynamics:

Driver:

Rising public awareness and parental demand

Families are increasingly opting to preserve umbilical cord blood and tissue for potential future use in regenerative therapies. Educational campaigns and prenatal counseling are improving understanding of stem cell applications in genetic and immune disorders. Hospitals and birthing centers are partnering with private banks to offer collection and storage services. Demand is rising across urban and semi-urban regions with growing access to maternity care. These dynamics are propelling market expansion across preventive and personalized medicine.

Restraint:

Limited proven indications

While stem cells show promise in treating blood cancers and metabolic disorders, most applications remain experimental or restricted to clinical trials. Regulatory bodies require rigorous validation before approving new therapeutic uses. Parents may hesitate to invest in banking without clear evidence of long-term benefit. Lack of standardized protocols for emerging indications slows integration into mainstream care. These limitations continue to hinder broader adoption and reimbursement support.

Opportunity:

Increased healthcare spending and private investment

Governments are funding biobanking initiatives and public-private partnerships to support regenerative medicine. Venture capital and institutional investors are backing startups focused on cryopreservation, analytics, and cell therapy integration. Expansion of fertility clinics and maternity hospitals is creating new collection points and referral networks. Demand for long-term biological storage is rising across oncology, neurology, and rare disease segments. These trends are fostering scalable and diversified growth across the stem cell banking ecosystem.

Threat:

Data privacy, consent and ethical transparency issues

Organizations must ensure secure handling of genetic and personal data linked to stored samples. Consent protocols must be clear, age-appropriate, and legally compliant across jurisdictions. Ethical concerns around commercialization, donor rights, and future use of samples require robust governance. Regulatory scrutiny is increasing across cross-border storage and research collaborations. These risks continue to constrain platform credibility and stakeholder engagement.

Covid-19 Impact:

The pandemic disrupted maternity care and elective procedures, temporarily reducing stem cell collection volumes. However, post-pandemic recovery has emphasized preventive health and biobanking as part of long-term resilience. Hospitals resumed cord blood collection and partnered with private banks to expand access. Public interest in immune health and regenerative therapies increased during the crisis. Investment in digital consent, remote counseling, and logistics improved operational continuity. These shifts are accelerating long-term integration of stem cell banking into maternal and pediatric care.

The umbilical cord stem cells segment is expected to be the largest during the forecast period

The umbilical cord stem cells segment is expected to account for the largest market share during the forecast period due to their accessibility, non-invasive collection, and broad therapeutic potential. Cord blood contains hematopoietic stem cells used in treating leukemia, anemia, and immune deficiencies. Cord tissue offers mesenchymal stem cells with applications in orthopedic and neurological conditions. Collection is safe and painless during childbirth, making it widely acceptable across cultures. Private and public banks are scaling cryopreservation and registry services for cord-derived samples. These capabilities are boosting segment dominance across clinical and research applications.

The sample analysis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the sample analysis segment is predicted to witness the highest growth rate as banks and research institutions expand testing and characterization services. Analysis includes viability testing, HLA typing, contamination screening, and potency assays. Integration with AI and genomic platforms is enabling predictive modeling and personalized therapy planning. Demand for validated, high-quality samples is rising across clinical trials and cell therapy pipelines. Vendors are offering bundled services that combine storage with analytics and reporting. These dynamics are accelerating growth across value-added biobanking services.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced healthcare infrastructure, regulatory clarity, and high parental awareness. The United States and Canada host major private and public stem cell banks with nationwide collection networks. Investment in regenerative medicine and personalized therapies is supporting platform expansion. Hospitals and insurers are integrating stem cell banking into maternity packages and wellness plans. Presence of leading biotech firms and academic research centers is driving innovation and standardization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as birth rates, healthcare access, and bio-banking initiatives converge. Countries like India, China, Japan, and South Korea are scaling stem cell banking across urban and tier-2 cities. Government-backed programs are supporting public awareness, infrastructure, and regulatory alignment. Local firms are launching affordable packages and multilingual counselling to reach diverse populations. Demand for sample analysis and regenerative therapies is rising across pediatric and chronic disease segments.

Key players in the market

Some of the key players in Stem Cell Banking Market include Cord Blood Registry (CBR), Cryo-Cell International, ViaCord, LifeCell International, StemCyte, China Cord Blood Corporation, Smart Cells International, CryoSave, BioEden, Cells4Life, Global Stem Cells Group, StemExpress, Vita 34 AG, ReeLabs and Cryoviva Biotech Pvt. Ltd.

Key Developments:

In July 2025, ViaCord launched its NextGen CryoPreserve(TM) platform, designed to enhance long-term viability of cord tissue stem cells. The system uses proprietary cryoprotectants and automated thawing protocols, improving therapeutic readiness for orthopedic, neurological, and autoimmune applications.

In May 2025, Cryo-Cell International partnered with Duke University's Marcus Center for Cellular Cures to advance cord blood therapies for autism and cerebral palsy. The collaboration supports FDA-regulated clinical trials and expands Cryo-Cell's therapeutic pipeline, reinforcing its leadership in translational stem cell research.

Source Types Covered:

• Umbilical Cord Stem Cells
• Cord Blood
• Cord Tissue
• Placenta
• Adult Stem Cells
• Bone Marrow
• Peripheral Blood
• Embryonic Stem Cells
• Other Source Types

Bank Types Covered:

• Private Stem Cell Banks
• Public Stem Cell Banks
• Hybrid Banks

Service Types Covered:

• Sample Collection & Transportation
• Sample Processing
• Sample Analysis
• Sample Preservation & Storage

Utilizations Covered:

• Used Samples
• Unused Samples

End Users Covered:

• Hospitals & Specialty Clinics
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies
• Patients & Families
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Stem Cell Banking Market, By Source Type

• 5.1 Introduction
• 5.2 Umbilical Cord Stem Cells
• 5.3 Cord Blood
• 5.4 Cord Tissue
• 5.5 Placenta
• 5.6 Adult Stem Cells
• 5.7 Bone Marrow
• 5.8 Peripheral Blood
• 5.9 Embryonic Stem Cells
• 5.10 Other Source Types

6 Global Stem Cell Banking Market, By Bank Type

• 6.1 Introduction
• 6.2 Private Stem Cell Banks
• 6.3 Public Stem Cell Banks
• 6.4 Hybrid Banks

7 Global Stem Cell Banking Market, By Service Type

• 7.1 Introduction
• 7.2 Sample Collection & Transportation
• 7.3 Sample Processing
• 7.4 Sample Analysis
• 7.5 Sample Preservation & Storage

8 Global Stem Cell Banking Market, By Utilization

• 8.1 Introduction
• 8.2 Used Samples
• 8.3 Unused Samples

9 Global Stem Cell Banking Market, By End User

• 9.1 Introduction
• 9.2 Hospitals & Specialty Clinics
• 9.3 Research & Academic Institutes
• 9.4 Pharmaceutical & Biotech Companies
• 9.5 Patients & Families
• 9.6 Other End Users

10 Global Stem Cell Banking Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Cord Blood Registry (CBR)
• 12.2 Cryo-Cell International
• 12.3 ViaCord
• 12.4 LifeCell International
• 12.5 StemCyte
• 12.6 China Cord Blood Corporation
• 12.7 Smart Cells International
• 12.8 CryoSave
• 12.9 BioEden
• 12.10 Cells4Life
• 12.11 Global Stem Cells Group
• 12.12 StemExpress
• 12.13 Vita 34 AG
• 12.14 ReeLabs
• 12.15 Cryoviva Biotech Pvt. Ltd.